Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hematopoietic stem cells and residual inflammatory cardiovascular risk in type 2 diabetes treated with semaglutide
2022-000404-35Phase 4Terminated
- Sponsor
- AMC Cardiovascular Sciences
- Start
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of semaglutide in type 2 diabetes mellitus (T2DM) and cardiac morbidity, sponsored by AMC Cardiovascular Sciences. Primary endpoint: Reduction in coronary 68Ga-Dotatate uptake. Started Apr 2022; status: terminated.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)cardiac morbidity
Beyond the preview
Go deeper on 2022-000404-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000404-35.